Latest NanOlogy News
-
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder CancerAugust 1, 2022 -
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast CancerMay 3, 2022 -
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of CareNovember 9, 2021 -
Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesionsAugust 25, 2021 -
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the PancreasJune 9, 2021 -
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical TrialApril 26, 2021 -
NanOlogy Completes Enrollment of Bladder Cancer Clinical TrialMarch 9, 2021 -
Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studiesNovember 10, 2020
